Based in London, Hughes will support Linden Thomson, manager of the AXA Framlington Biotech Fund and Dani Saurymper, manager of the AXA Framlington Health Fund. With a particular focus on biotechnology, he will join the healthcare team as a healthcare equity analyst.
Hughes joins AXA from an investment analyst role at Architas. He holds a masters in chemistry from The University of Surrey and a PhD in biochemistry focused on drug development from University College London.
“Working at Architas has been a great introduction to the asset management industry and we believe his PhD in biochemistry and masters in chemistry serve him well for a position in the sector,” said Linden Thomson, manager of the AXA Framlington Biotech fund.
